Clinical manifestations and diagnosis of cutaneous leishmaniasis
- Naomi Aronson, MD
Naomi Aronson, MD
- Professor of Medicine
- Uniformed Services University
Leishmaniasis consists of a complex of vector-borne diseases caused by a heterogeneous group of protozoa belonging to the genus Leishmania; it is transmitted by sand fly vectors. Clinical manifestations range from cutaneous ulcers to systemic multiorgan disease. Specific organisms are frequently associated with a typical clinical picture (table 1), although this can be variable.
The clinical manifestations and diagnosis of cutaneous leishmaniasis will be reviewed here. Issues concerning treatment, epidemiology, and control are discussed separately. (See "Treatment of cutaneous leishmaniasis" and "Epidemiology and control of cutaneous leishmaniasis".)
The incubation period for symptomatic cutaneous leishmaniasis (CL) ranges from weeks to months; mucosal involvement may occur years following initial infection [1,2]. Asymptomatic infection may occur in about 10 percent of patients; this has been suggested by delayed hypersensitivity skin testing .
Leishmania causes a spectrum of cutaneous disease. The range of clinical manifestations may be attributed to variability in parasite virulence (and other intrinsic characteristics) and variability in the host immune response. At one end of the spectrum, mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease associated with a marked cellular immune response. The center of the spectrum consists of localized cutaneous leishmaniasis (LCL), which is the most common clinical presentation. At the opposite end of the spectrum, diffuse cutaneous leishmaniasis (DCL) is caused by polyparasitic disease with a predominance of parasitized macrophages and no granulomatous inflammation. This spectrum of clinical presentation and host immune response is similar to clinical manifestations observed in the setting of leprosy . (See "Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy".)
The cutaneous syndromes associated with Leishmania parasite infection include LCL, LR, DCL, and ML. These will be further described below; they are presented in order of relative clinical frequency.
- Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13:1009.
- Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156:73.
- Follador I, Araújo C, Bacellar O, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34:E54.
- Convit J, Ulrich M, Fernández CT, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87:444.
- Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14:425.
- Sousa Ade Q, Parise ME, Pompeu MM, et al. Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg 1995; 53:380.
- Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518.
- Barral A, Guerreiro J, Bomfim G, et al. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995; 53:256.
- Kubba R, Al-Gindan Y, el-Hassan AM, Omer AH. Clinical diagnosis of cutaneous leishmaniasis (oriental sore). J Am Acad Dermatol 1987; 16:1183.
- Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis 2001; 33:1076.
- Develoux M, Diallo S, Dieng Y, et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal. Trans R Soc Trop Med Hyg 1996; 90:396.
- Guerra JA, Prestes SR, Silveira H, et al. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 2011; 5:e980.
- Shirian S, Oryan A, Hatam GR, Daneshbod Y. Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health 2013; 107:267.
- Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859.
- Boaventura VS, Santos CS, Cardoso CR, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40:2830.
- Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011; 331:775.
- Motta AC, Arruda D, Souza CS, Foss NT. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 2003; 42:703.
- Tuon FF, Sabbaga Amato V, Floeter-Winter LM, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report. Int J Dermatol 2007; 46:628.
- Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012; 71 Suppl 2:i60.
- Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.
- Mirzabeigi M, Farooq U, Baraniak S, et al. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006; 33:701.
- Mendonça MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.
- Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 2009; 160:311.
- Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81:559.
- Couppié P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165.
- Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45:478.
- Douba MD, Abbas O, Wali A, et al. Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 2012; 26:1224.
- Boggild AK, Ramos AP, Espinosa D, et al. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:345.
- Kreutzer RD, Christensen HA. Characterization of Leishmania spp. by isozyme electrophoresis. Am J Trop Med Hyg 1980; 29:199.
- de Almeida ME, Steurer FJ, Koru O, et al. Identification of Leishmania spp. by molecular amplification and DNA sequencing analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol 2011; 49:3143.
- Mouri O, Morizot G, Van der Auwera G, et al. Easy identification of leishmania species by mass spectrometry. PLoS Negl Trop Dis 2014; 8:e2841.
- Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.
- The SMART Leish http:/www.accessdata.fda.gov/cdrh_docs/pdf8/K081868.pdf (Accessed on September 04, 2012).
- Antinori S, Calattini S, Piolini R, et al. Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am J Trop Med Hyg 2009; 81:46.
- Marfurt J, Niederwieser I, Makia ND, et al. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46:115.
- Romero GA, de la Glória Orge Orge M, de Farias Guerra MV, et al. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop 2005; 93:49.
- Hartzell JD, Aronson NE, Weina PJ, et al. Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 79:843.
- Shaw JJ, Lainson R. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1975; 69:323.
- Turgay N, Balcioglu IC, Toz SO, et al. Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg 2010; 83:822.
- CLINICAL MANIFESTATIONS
- Localized cutaneous leishmaniasis (LCL)
- - Differential diagnosis
- Leishmaniasis recidivans (LR)
- Diffuse cutaneous leishmaniasis (DCL)
- Mucosal leishmaniasis (ML)
- CL in immunocompromised hosts
- Clinical approach
- - Clinical history
- - Physical examination
- Specimen collection
- Diagnostic tools
- - Histology
- - Culture
- - Molecular diagnostic techniques
- Other assays
- - Serology
- - Skin test
- DIFFERENTIAL DIAGNOSIS